POSITIVE / NEGATIVE RESULT ON GENETIC ALTERATIONS TESTED
ForeSENTIA is a new generation test that identifies genetic alterations involved in cancer. It consists of an extensive portfolio of cancer panels, which provide accurate molecular analysis of the tumor sample taken during biopsy. There are two panel categories, both of which offer indispensable prognostic value, guidance on treatment decisions and increased chance of successful treatment through precision medicine and targeted therapies.
Comprehensive tumor profile panels: Wider coverage of genes implicated in specific cancer types
Therapy-associated tumor profile panels: for selected clinically actionable alterations that are related to targeted therapies.
ADVANTAGES OF ForeSENTIA:
- Extensive analysis of clinically actionable genetic alterations
- Detailed molecular classification of the tumor
- Targeted therapy selection guidance
- Improved prognostic assessment
- Informed clinical management
- Precision technology
- High sensitivity & specificity
WHAT WILL THE ForeSENTIA REPORT TELL ME?
GUIDANCE ON APPROVED TARGETED THERAPIES AND CLINICAL TRIALS
COMPREHENSIVE ANALYSIS ON FINDINGS
COMPREHENSIVE TUMOR PROFILE PANELS
for wide coverage of genes implicated in specific cancer types
Comprehensive tumor profile panels test for an extensive number of clinically actionable genetic alterations that are frequently implicated in solid tumors; therefore giving the healthcare provider a complete molecular profile of the tumor.
- Detailed molecular classification
- Deep investigation of tumor heterogeneity
- Better chances of identifying disease-causing variants
-
BREAST / OVARIAN
44
-
COLORECTAL
33
-
LUNG (NSCLC)
35
-
PROSTATE
27
-
MELANOMA
21
-
GLIOMA
22*
-
PAN-CANCER
76*
* 1p/19q codeletion is also tested in these panels and reported only in the context of glioma diagnosis.
BREAST/OVARIAN TUMOR PROFILE PANEL
Description
The ForeSENTIA breast/ovarian tumor profile panel tests for numerous genetic alterations that are frequently found in breast or ovarian tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with breast or ovarian cancer can have tumor profile testing with the ForeSENTIA breast/ovarian panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
44
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA beast/ovarian tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Breast/Ovarian Tumor Profile Panel
Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
---|---|---|
AKT1, ATM, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CHEK2, CTNNB1, DICER1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FOXA1, FOXL2, GATA3, KIT, KRAS, MAP3K1, MRE11A, MTOR, NBN, NRAS, PALB2, PIK3CA, PIK3CB, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, TP53 | EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN, TP53 | NTRK1, NTRK2, NTRK3 |
COLORECTAL TUMOR PROFILE PANEL
Description
The ForeSENTIA colorectal tumor profile panel tests for numerous genetic alterations that are frequently found in colorectal tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with colorectal cancer can have tumor profile testing with the ForeSENTIA colorectal cancer panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
33
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA colorectal tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Colorectal Tumor Profile Panel
Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
---|---|---|
AKT1, APC, ATM, BRAF, BRCA1, BRCA2, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MLH1, MSH2, MSH6, MTOR, NRAS, NTRK1, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAF1, SMAD4, TP53 | EGFR, ERBB2, FGFR1, FGFR2, FGFR3, KRAS, MET, TP53 | NTRK1, NTRK2, NTRK3 |
LUNG (NSCLC) TUMOR PROFILE PANEL
Description
The ForeSENTIA lung (NSCLC) tumor profile panel tests for numerous genetic alterations that are frequently found in lung (Non Small Cell Lung Cancers – NSCLC) tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with lung (NSCLC) cancer can have tumor profile testing with the ForeSENTIA lung (NSCLC) panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
35
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA lung (NSCLC) tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Lung (NSCLC) Tumor Profile Panel
Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
---|---|---|
AKT1, ALK, APC, ARAF, ATM,BRAF, BRCA2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, FBXW7, JAK2, KEAP1, KRAS, MAP2K1, MET, NRAS, PIK3CA, POLE, PTEN, RAF1, SMAD4, STK11, TP53 | EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, PIK3CA, PTEN, TP53 | ALK, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1 |
MELANOMA TUMOR PROFILE PANEL
Description
The ForeSENTIA melanoma tumor profile panel tests for numerous genetic alterations that are frequently found in melanomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with melanoma cancer can have tumor profile testing with the ForeSENTIA melanoma panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
21
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA melanoma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Prostate Tumor Profile Panel
Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
---|---|---|
AKT1, BRAF, CTNBB1, ERBB2, GNA11, GNAQ, KIT, KRAS, MAP2K1, NF1, NRAS, PIK3CA, POLE, PTEN, TP53 | ERBB2, KIT, KRAS, MYC, TP53 | ALK, BRAF, NTRK1, NTRK2, NTRK3, RET, ROS1 |
PROSTATE TUMOR PROFILE PANEL
Description
The ForeSENTIA prostate tumor profile panel tests for numerous genetic alterations that are frequently found in prostate tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with prostate cancer can have tumor profile testing with the ForeSENTIA prostate panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
27
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA prostate tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Prostate Tumor Profile Panel
Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
---|---|---|
AKT1, APC, AR, ATM, BRAF, BRCA1, BRCA2, CTNNB1, FOXA1, NRAS, PALB2, PIK3CA, PIK3CB, POLE, PTEN, SPOP, TP53 | AR, ERBB2, FGFR1, FGFR2, FGFR3, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 | TMPRSS2 |
GLIOMA TUMOR PROFILE PANEL
Description
The ForeSENTIA glioma tumor profile panel tests for numerous genetic alterations that are frequently found in gliomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with glioma cancer can have tumor profile testing with the ForeSENTIA glioma panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
22
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA glioma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Glioma Tumor Profile Panel
Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
---|---|---|
ATRX, BRAF, CIC, CTNNB1, EGFR, FUBP1, H3F3A, IDH1, IDH2, NF1, POLE, TERT, TP53 | 1p/19q codeletion, CDKN2A, EGFR, MET, MYC, MYCN, PTEN | BRAF, FGFR3, NF1, NTRK1, NTRK2, NTRK3 |
PAN-CANCER TUMOR PROFILE PANEL
Description
The ForeSENTIA pan-cancer tumor profile panel tests for numerous genetic alterations that are frequently found in several cancers. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.
Who is this test for?
Any patient diagnosed with cancer can have tumor profile testing with the ForeSENTIA pan-cancer panel to help identify the specific genetic alterations that are associated with their tumor.
Number Of Genes Tested
76
Sample: Unstained sections from tumor biopsy sample
Turnaround time: 2-3 Weeks
Genes Tested
The table below shows the genes tested by the ForeSENTIA pan-cancer tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.
ForeSENTIA Pan-Cancer Tumor Profile Panel
Single Nucleotide Variants / Insertions and Deletions | Copy Number Alterations | Translocations |
---|---|---|
AKT1, ALK, APC, AR, ARAF, ATM, ATRX, BARD1, BRAF, BRCA1,BRCA2, BRIP1, CHEK2, CIC, CTNNB1,DDR2, DICER1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FBXW7, FOXA1, FOXL2, FUBP1, GATA3,GNA11, GNAQ, GNAS, H3F3A, IDH1, IDH2, JAK2, KEAP1, KIT, KRAS, MAP2K1, MAP3K1, MET, MLH1, MRE11A, MSH2, MSH6, MTOR, NBN, NF1, NRAS, NTRK1, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, SPOP, STK11, TERT, TP53 | 1p/19q codeletion, AR, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KIT, KRAS, MET, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 | ALK, BRAF, FGFR3, NF1, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2 |
THERAPY-ASSOCIATED TUMOR PROFILE PANELS
for selected clinically actionable alterations that are related to targeted therapies
Therapy-associated tumor profile panels test for single nucleotide variants (SNVs), insertions and deletions on selected hotspot regions of 1 or 2 genes that are frequently involved in a variety of tumors. Testing of these genes is routinely requested by healthcare professionals due to their implication in tumors. There are several approved* targeted therapies and ongoing clinical trials focusing on these genes.
- Clinically-actionable, therapy-related alterations
- Shorter turn-around time
Lung
Melanoma
Endometrial
Colorectal
Adenocarcinoma
Breast
Pancreatic
Colorectal
Lung
Melanoma
Thyroid
Bladder
Endometrial
Thymoma
Testicular
Breast
Endometrial
Colorectal
Cervical
Head and Neck
Bladder
Lung
Melanoma
Thyroid
Colorectal
Endometrial
Lung
Glioma
*FDA (Food and Drug Administration), EMA (European Medicines Agency), PMDA (Pharmaceuticals and Medical Devices Agency, Japan) HCSC (Health Canada Santé Canada)
WHY RECOMMEND ForeSENTIA TO MY PATIENTS?
By thoroughly analyzing the tumor sample for clinically actionable genetic alterations involved in carcinogenesis, ForeSENTIA allows targeted and precise patient treatment.
With ForeSENTIA, you ensure that your patients will have the best therapy option for them - which will improve their chances of survival.

WHAT CAN I DO TO HELP MY PATIENTS AFTER ForeSENTIA?
With the information gained by ForeSENTIA, you will be able to:
- Prescribe the most suitable therapies for your patients
- Provide your patients accurate prognosis
- Identify appropriate clinical trials to enroll your patient
WHAT DOES ForeSENTIA DETECT?
ForeSENTIA detects the 4 main types of genetic alterations known to be implicated in cancer:
Click here to view the table of genes tested by the ForeSENTIA Tumor Profile Panels, and whether the genes examined are tested for Single Nucleotide Variants(SNVs) / Insertions and Deletions, Copy Number Alterations (CNAs), translocations or a combination of variants
WHY CHOOSE ForeSENTIA?
ForeSENTIA thoroughly analyzes the tumor sample for numerous clinically actionable mutated genes involved in cancer development. It is cost effective, time sensitive and clinically valuable.
WHAT ARE THE BENEFITS FOR MY PATIENTS?
- Ability to select a panel that is most suitable to them
- Knowledge of eligible clinical trials
- Invaluable prognostic insight
- Lower risk of ineffective therapy and adverse effects
- Higher chances of successful treatment and survival
TECHNOLOGY YOU TRUST
ForeSENTIA uses novel, target capture enrichement technology proven for its precision and accuracy. Analysis of selection regions is performed at an extremely high read-deapth, improving the statistical accuracy of the results. Lastly, genetic and bioinformatics approaches, and multi-engine analysis pipelines have been specifically incorporated to raise the sensitivity and specificity of ForeSENTIA.
TARGETED TECHNOLOGY
ForeSENTIA is based on a novel, target capture enrichment technology that has been validated for its accuracy and precision.

HIGH READ DEPTH
Specifically-designed analytical methods have been incorporated to ensure high read-depth, raising the sensitivity and specificity of the test.
MULTI-ENGINE ANALYSIS
Proprietary bioinformatics pipelines analyze the sequencing data produced from each sample, increasing the sensitivity and specificity of ForeSENTIA
WHAT IS THE POSITION OF PROFESSIONAL BODIES ON PRECISION MEDICINE?
Molecular tumor profiling has become a routine part of cancer patient care. It can help healthcare providers avoid a ‘one-size-fits-all’ approach and instead choose tailored treatments that improve survival chances for cancer patients and spare them potential side effects from drugs that are unlikely to be beneficial. Such advancements in technology and genomics can help physicians in diagnosing, treating and understanding more about human disease, and in selecting treatment that is most likely to help patients.
Source: Food and Drug Administration (FDA), National Comprehensive Cancer Network (NCCN), American Cancer Society, European Society for Medical Oncology (ESMO), Cancer.Net and National Cancer Institute
HOW TO ADMINISTER ForeSENTIA?
-
RECOMMEND THE IDEAL PANEL TO YOUR PATIENT
LET THE HISTOPATHOLOGY LAB KNOW THAT ADDITIONAL TESTING WILL BE REQUIRED ON THE TISSUE BIOPSY SAMPLE
THE HISTOPATHOLOGY LAB WILL SEND US THE TUMOR SECTIONS
THE RESULTS WILL BE SENT TO YOU IN 2-3 WEEKS
Depending on the results, guidance on finding the most appropriate targeted therapies and clinical trials will be provided.